10-K: Palisade Bio Secures $127.6M, Advances IBD Drug PALI-2108

Palisade Bio reported positive Phase 1 clinical trial results for its lead IBD drug candidate PALI-2108, secured $127.6 million in financing, and outlined plans for Phase 2 studies in 2026.

Summary

• Palisade Bio is a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
• The lead product candidate, PALI-2108, is designed for targeted delivery to the terminal ileum and colon to reduce systemic toxicity and improve tolerability.
• The company completed a Phase 1 clinical study of PALI-2108 in Canada, which met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) in healthy volunteers and UC patients.
• Preliminary results from the UC cohort showed rapid and consistent clinical activity, with all five patients responding to treatment, though these results require validation in randomized, controlled trials.
• An exploratory Phase 1b cohort for Fibrostenotic Crohn's disease (FSCD) was initiated on October 16, 2025, to evaluate safety, tolerability, PK, and pharmacodynamics (PD) over a 14-day treatment period.
• Palisade Bio plans to submit Investigational New Drug (IND) applications to the FDA for a Phase 2 UC study in Q2 2026 and a Phase 2 CD study in H2 2026.
• The company completed an underwritten public offering on October 2, 2025, raising net proceeds of approximately $127.6 million.
• A warrant inducement transaction in July 2025 generated approximately $3.4 million in net cash proceeds.
• The Crohn's & Colitis Foundation (CCF) agreed to provide up to a $0.5 million investment to support the Phase 1b research program for PALI-2108.
• As of December 31, 2025, Palisade Bio had $133.4 million in cash, cash equivalents, and restricted cash.
• The company reported a net loss of $16.8 million for the year ended December 31, 2025, compared to $14.4 million in 2024.
• Research and development expenses increased by 12% to $10.2 million in 2025, primarily due to increased clinical trial activity for PALI-2108 and higher employee-related costs.
• General and administrative expenses increased by 36% to $7.9 million in 2025, driven by higher employee-related expenses and professional fees.
• The company maintains a full valuation allowance on all deferred tax assets due to a history of operating losses.
• A material weakness in internal controls over financial reporting, related to financial closing and reporting processes, remains present as of December 31, 2025, with remediation efforts ongoing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the successful Phase 1 clinical trial results for PALI-2108, particularly the promising preliminary efficacy signals in UC patients, and the significant capital raise that provides a strong runway for advancing the lead candidate into Phase 2 studies. While the company still faces substantial risks and operating losses, the financial stability and clinical progress are encouraging for its stage of development.

Positives

• PALI-2108's Phase 1 clinical study successfully met its primary endpoints of safety, tolerability, and pharmacokinetics in healthy volunteers and UC patients.
• The UC cohort demonstrated rapid and consistent clinical activity, with all five patients responding to treatment, indicating potential efficacy.
• Initiation of an exploratory Phase 1b cohort in Fibrostenotic Crohn's disease (FSCD) expands the potential indications for PALI-2108, addressing a significant unmet medical need with no FDA-approved treatments.
• The company secured substantial financing of approximately $127.6 million from an October 2025 public offering and $3.4 million from a July 2025 warrant inducement transaction, significantly bolstering its cash position.
• Management believes the current capital is sufficient to fund operations through major clinical development milestones, including Phase 2 primary efficacy readouts for UC (H2 2027) and CD (2028).
• A research funding agreement with the Crohn's & Colitis Foundation provides up to $0.5 million to support the Phase 1b research program.
• The company received a Notice of Allowance for its PALI-2108 patent in China (July 2025) and a patent grant in Japan (December 2025), strengthening its intellectual property portfolio.
• The company's precision medicine approach, utilizing biomarker-based patient selection, aims to improve response rates and differentiate PALI-2108 in the IBD market.

Negatives

• Palisade Bio has a limited operating history and has never generated any revenues from product sales, relying heavily on equity financings.
• The company has a history of net operating losses and expects to continue incurring them for the foreseeable future, with a net loss of $16.8 million in 2025.
• A material weakness in internal controls over financial reporting, specifically regarding financial closing and reporting processes, remains un-remediated as of December 31, 2025.
• The company is highly dependent on third-party Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) for clinical trials and drug supply, introducing external risks.
• There is no assurance that the FDA will accept data from Canadian clinical trials for US regulatory approval, potentially requiring additional US-based trials.
• The failure of Alto Neuroscience's Phase 2b study of ALTO-100 (formerly NSI-189) in major depressive disorder (MDD) could impact potential milestone payments to Palisade Bio, although it is still being evaluated for bipolar depression.
• The company will require substantial additional capital beyond 2028 to fund Phase 3 clinical trials and potential commercialization of PALI-2108.
• The company's common stock price has been highly volatile and was subject to Nasdaq delisting concerns due to the Bid Price Rule in 2023 and 2025, though compliance was regained.

Risks

• Business depends on the successful clinical development, regulatory approval, and commercialization of PALI-2108, which is subject to substantial risks inherent in drug development.
• Dependence on the license agreement with Giiant Pharma Inc. for PALI-2108 patents; termination or non-compliance could materially harm the business.
• The FDA or applicable foreign regulatory authorities may not accept data from clinical trials conducted outside the U.S., potentially delaying or preventing US approval.
• Difficulty enrolling patients in clinical trials could delay or prevent the completion of studies for product candidates.
• Operations and development of PALI-2108 will require more capital than currently available, and securing additional funding on acceptable terms is not guaranteed, leading to potential curtailment of trials or operations.
• PALI-2108 may cause undesirable side effects or have other unexpected properties, delaying regulatory approval, limiting commercial profile, or resulting in post-approval regulatory action.
• There is no assurance that product candidates will obtain regulatory approval, and clinical studies of PALI-2108 may not yield successful results, leading to discontinuation of development.
• Clinical trials may take longer than estimated to complete, or may not be completed at all.
• Recent and future changes in healthcare legislation and regulations may increase the difficulty and cost to obtain marketing approval, commercialize products, and adversely affect pricing.
• Business operations and relationships with third parties are subject to applicable healthcare regulatory laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), which could expose the company to penalties.
• Inability to successfully in-license, acquire, develop, and market additional product candidates or approved products could impair business growth.
• Changes in funding for the FDA and other government agencies could hinder their ability to perform normal business functions, negatively impacting the company's business.
• Reliance on third-party Contract Research Organizations (CROs) and other third parties to conduct and oversee clinical trials; failure to meet requirements could prevent regulatory approval or commercialization.
• Dependence on two qualified suppliers for the active pharmaceutical ingredient (API) for PALI-2108; insufficient availability or inability of suppliers to manufacture on commercially reasonable terms could adversely impact the business.
• Reliance on collaborations with third parties for successful development and commercialization of product candidates, which are subject to significant risks.
• Potential product liability exposure from clinical trials and commercial sales, which could result in substantial costs and liabilities.
• Even if approved, PALI-2108 may fail to achieve broad physician and patient adoption and use necessary for commercial success.
• Inability to obtain, maintain, or enforce global patent rights or other intellectual property rights of sufficient breadth to prevent third-party competition.
• Failure to comply with obligations under intellectual property license agreements could result in loss of critical license rights.
• Potential patent infringement claims, leading to substantial costs and liabilities.
• Claims that officers, directors, employees, or consultants have wrongfully used or disclosed trade secrets of former employers or customers.
• Future sales of substantial amounts of common stock, or the possibility of such sales, could adversely affect the market price and dilute existing stockholders.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management.
• Business could be adversely affected by health pandemics or epidemics, such as COVID-19, causing disruptions in operations and those of third-party partners.
• Global economic conditions, including inflation, interest rate increases, tariffs, and trade restrictions, could adversely affect the business and ability to raise capital.
• Inadequate funding for the FDA, SEC, and other government agencies, including from government shutdowns, could hinder their operations and delay regulatory processes.
• Compromise of information systems or data, or those of third parties, could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• The BIOSECURE Act could restrict the ability to pursue U.S. federal government business if current Chinese suppliers are designated as biotechnology companies of concern.

Future Outlook

Palisade Bio anticipates submitting Investigational New Drug (IND) applications to the FDA for a Phase 2 UC study in the second quarter of 2026 and a Phase 2 CD study in the second half of 2026. The company expects its clinical research and development costs to continue increasing in 2026 as PALI-2108 advances through clinical studies. Management believes current capital is sufficient to fund operations through major clinical development milestones, including Phase 2 primary efficacy readouts for UC in H2 2027 and CD in 2028, but acknowledges the need for additional financing beyond 2028 for Phase 3 trials and potential commercialization.

Management Comments

• Management believes PALI-2108 has the potential to provide a much-needed first-in-class therapy for patients with Fibrostenotic Crohn's disease (FSCD) given the lack of effective treatment options.
• Management believes that localized bioactivation of PALI-2108 may help focus its effects where it would be most beneficial to a patient suffering from IBD, while preventing systemic toxicity and known tolerability issues of PDE4 inhibitors.
• Management believes the October 2025 Offering for net proceeds of $127.6 million will provide sufficient capital to fund operations through major clinical development milestones including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 for CD that is expected in 2028.
• Management has concluded that because of the net proceeds raised from the recent equity offering, there is no longer a substantial doubt about the company's ability to continue as a going concern for a period of one year following the date these consolidated financial statements are issued.

Industry Context

StockSavvy.ai notes that Palisade Bio is operating in a highly competitive biopharmaceutical landscape, particularly within the IBD treatment sector. The company's focus on a locally acting PDE4 inhibitor prodrug, PALI-2108, and a precision medicine approach aims to address significant unmet needs in IBD, such as inadequate primary response, secondary loss of response, and tolerability issues associated with systemic PDE4 inhibitors. The IBD market, including UC and CD, is substantial and projected to grow, with UC treatments expected to exceed $9.5 billion by 2031 and CD treatments reaching approximately $25.5 billion by 2032. The lack of FDA-approved pharmacologic treatments for FSCD positions PALI-2108 as a potential first-in-class therapy, offering a unique opportunity. However, the industry is dominated by large pharmaceutical companies with extensive resources and established pipelines, such as AbbVie, Johnson & Johnson, Takeda, and Pfizer, which pose significant competitive challenges. Emerging biotech companies also contribute to a crowded development pipeline for IBD therapies. Palisade Bio's strategy to differentiate through targeted delivery and biomarker-based patient selection is crucial in this environment.

Comparison to Industry Standards

• Palisade Bio's PALI-2108, as a PDE4 inhibitor, competes with existing TNF antibodies like Humira (AbbVie) and Remicade (Johnson & Johnson), IL-12/23 antibodies like Stelara (Johnson & Johnson), IL-23 antibodies like Skyrizi (AbbVie), and JAK inhibitors like Xeljanz (Pfizer) and Rinvoq (AbbVie). These established therapies have significant market share and a track record of efficacy, but often come with systemic side effects or black box warnings that PALI-2108 aims to mitigate through its targeted delivery.
• The company's focus on Fibrostenotic Crohn's disease (FSCD) addresses a critical unmet need, as there are currently no FDA-approved or effective pharmacologic treatments. This positions PALI-2108 uniquely compared to competitors whose products primarily target inflammatory aspects of IBD without specific anti-fibrotic mechanisms for FSCD.
• The preliminary positive Phase 1 results for PALI-2108 in UC patients, showing rapid and consistent clinical activity, are encouraging for an early-stage asset, but require further validation in larger, controlled Phase 2 and 3 trials to demonstrate superiority or non-inferiority against established treatments.
• Palisade Bio's biomarker-based patient selection approach aligns with a growing industry trend towards personalized medicine, similar to successful applications in oncology, which could enhance treatment efficacy and patient outcomes compared to broad-spectrum therapies.
• The company's reliance on third-party manufacturing and CROs is a common industry practice for clinical-stage biopharmaceutical companies, but introduces supply chain and regulatory compliance risks that larger, integrated pharmaceutical companies might manage internally.

Corporate Governance

Legal Proceedings

• No claims or actions pending against the company through December 31, 2025, are believed to have a material adverse effect on its business, liquidity, financial position, or results of operations.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent equity offerings (October 2025 Offering, July 2025 Warrant Inducement) and potential future capital raises. Stock price volatility and delisting risks remain concerns, though Nasdaq compliance was regained. Potential for long-term value creation if PALI-2108 successfully progresses through clinical trials and achieves commercialization.
• **Employees**: Increased research and development headcount (133% increase in R&D employee-related expenses) to support PALI-2108 development. Compensation programs are designed to align interests with growth and stockholder returns. Comprehensive benefits and 401(k) plan (with matching contributions effective Jan 1, 2026) aim to attract and retain talent.
• **Customers (future)**: PALI-2108 aims to address significant unmet needs in IBD, potentially offering improved pharmacology, tolerability, and convenience compared to existing treatments, especially for FSCD patients with limited options.
• **Creditors**: The substantial capital raise significantly improves the company's liquidity and ability to meet its financial obligations in the near to medium term, reducing immediate credit risk.
• **Partners (Giiant Pharma, Alto Neuroscience, University of Michigan, Newsoara)**: Continued collaboration and potential milestone/royalty payments for Giiant. Alto's ALTO-100 progress (despite MDD setback) could still yield future milestone payments. Newsoara agreement for LB1148 (ceased development) continues to exist for potential future payments. University of Michigan collaboration for NSI-532.IGF-1 involves shared revenue from licensing.

Next Steps

• Complete longer-term chronic safety and toxicology studies for PALI-2108.
• Continue evaluation of safety, tolerability, PK, and PD in the exploratory Phase 1b cohort in Fibrostenotic Crohn's disease (FSCD).
• Initiate Phase 2 clinical programs to assess PALI-2108's efficacy, safety, and tolerability in patients with moderate to severe UC and CD.
• Submit Investigational New Drug (IND) applications to the FDA for a Phase 2 UC study in Q2 2026.
• Submit Investigational New Drug (IND) applications to the FDA for a Phase 2 CD study in H2 2026.
• Achieve Phase 2 primary efficacy readout of PALI-2108 for UC in H2 2027.
• Achieve Phase 2 primary efficacy readout of PALI-2108 for CD in 2028.
• Remediate the identified material weakness in internal controls over financial reporting.
• Seek additional financing beyond 2028 to fund Phase 3 clinical trials and potential commercialization of PALI-2108.

Key Dates

Recommendation

Palisade Bio presents a mixed but cautiously optimistic picture for a seasoned investor. The positive Phase 1 clinical data for PALI-2108, particularly the early efficacy signals in UC, is a significant de-risking event for an early-stage biopharmaceutical company. The substantial capital raise of $127.6 million provides a strong financial runway through key Phase 2 milestones in 2027 and 2028, addressing immediate liquidity concerns and removing the 'going concern' doubt. However, the company remains pre-revenue, with a history of losses, and faces the inherent high risks and long timelines of drug development, including potential challenges in Phase 2 and 3 trials, regulatory hurdles, and intense competition. The un-remediated material weakness in internal controls also warrants attention. Given the early but promising clinical progress and strengthened balance sheet, a 'hold' recommendation is appropriate. Investors should monitor the upcoming Phase 2 IND submissions and subsequent trial readouts, as these will be critical catalysts for future valuation, while acknowledging the significant execution risks that remain.

Keywords

PALI-2108, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, PDE4 inhibitor, Clinical Trials, Biopharmaceutical, Drug Development, SEC Filing, Biomarkers, Fibrostenotic Crohn's Disease, Capital Raise, Nasdaq